IP Library Granted Patent US 12,303,686
Granted Patent B2
US 12,303,686 · App. 17/046,687 · Granted May 20, 2025

Midfield power source for wireless implanted devices

Inventors: Alexander Yeh (Los Altos Hills, CA); Hui Zhang (Newark, CA); Thomas Burpee Ellsworth, III (San Jose, CA); Elia Junco (Palo Alto, CA); Stephen James Schellenberg (Aptos, CA); Carl Lance Boling (San Jose, CA)
Assignee: NEUSPERA MEDICAL INC.
A61N1/08A61N1/37229A61N1/37252A61N1/375A61N1/3787H01Q1/38H02J50/20A61N1/025A61N1/05A61N1/3605A61N1/37205H01G4/35
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,303,686
App. No.
17/046,687
Filed
Oct 9, 2020
Granted
May 20, 2025
Kind
B2
Art Unit
3796
USPC
607/60
Abstract

Systems, devices, and methods discussed herein include wireless midfield transmitters and implantable receiver devices. A midfield transmitter can be configured to provide signals outside of tissue that give rise to propagating signals inside of tissue. The present subject matter includes a protection circuit for a transmitter device, a layered transmitter device, an implantable receiver device, implantation and extraction methods, test and assembly methods, and the like. In an example, a protection circuit includes a first control circuit to receive an RF drive signal and conditionally provide an output signal to an antenna. A second control circuit can generate a control signal based on the antenna output signal and/or information about the RF drive signal. A gain circuit can provide the RF drive signal to the first control circuit. The gain circuit can change an amplitude of the RF drive signal based on the control signal from the second control circuit.

Claims (51)

1. A tunable transmitter comprising:

an excitation structure configured to receive an excitation signal;

a first substrate;

a first emitter comprising first and second conductive regions excitable by the excitation structure in response to the excitation structure receiving the excitation signal, wherein the first and second conductive regions are provided on a first surface of the first substrate and the first and second conductive regions are spaced apart from the excitation structure and the first and second conductive regions are electrically decoupled from each other on the first surface of the first substrate and from the excitation structure, and wherein an insulator electrically separates the first and second conductive regions; and

a variable capacitor coupling the first and second conductive regions of the first emitter, the variable capacitor being configured to adjust a capacitance characteristic of the first emitter to tune a resonant frequency of the tunable transmitter based on at least one of a reflection coefficient or feedback information from a receiver device.

2. The tunable transmitter of claim 1 , further comprising a control circuit configured to provide an indication about whether the tunable transmitter is or is likely to be near body tissue based on information about the reflection coefficient.

3. The tunable transmitter of claim 1 , wherein the excitation structure comprises a stripline provided on a second surface adjacent and parallel to the first substrate, the stripline extending at least partially over the first emitter.

4. The tunable transmitter of claim 3 , wherein the first conductive region of the first emitter comprises an inner disc region and the second conductive region of the first emitter comprises an outer annular region, and wherein the stripline extends at least partially over the inner disc region of the first emitter.

5. The tunable transmitter of claim 4 , wherein the inner disc region and the outer annular region have substantially the same surface area.

6. The tunable transmitter of claim 1 , further comprising:

a ground plane; and

a second substrate, wherein the second substrate is provided between the ground plane and the excitation structure.

7. The tunable transmitter of claim 1 , wherein the tunable transmitter is configured to generate an adaptive steering field in tissue, wherein the adaptive steering field has a frequency between about 300 MHz and 3000 MHz.

8. The tunable transmitter of claim 1 , further comprising an excitation circuit configured to provide the excitation signal to the excitation structure, the excitation signal having a frequency between about 300 MHz and 3000 MHz.

9. The tunable transmitter of claim 1 , wherein a capacitance value of the variable capacitor is configured to be updated based on the reflection coefficient or based on the feedback from the receiver device.

10. The tunable transmitter of claim 1 , further comprising:

a signal generator coupled to the excitation structure; and

processing circuitry configured to:

cause the signal generator to energize the excitation structure with a first drive signal having a first frequency; and

sweep parameter values of the variable capacitor to change a capacitive coupling between the first and second conductive regions of the first emitter to thereby tune the first emitter to multiple different resonant frequencies at respective multiple instances.

11. The tunable transmitter of claim 10 , wherein the processing circuitry is further configured to:

for each of the multiple different resonant frequencies, detect respective amounts of power reflected by the first emitter when the first emitter is energized by the first drive signal;

identify a particular parameter value, among the swept parameter values, of the variable capacitor corresponding to a detected minimum amount of power reflected by the first emitter; and

programming the variable capacitor to the particular parameter value to communicate power and/or data to an implanted device using a wireless propagating wave inside body tissue.

12. The tunable transmitter of claim 11 , wherein the processing circuitry is further configured to:

based on information about capacitance value states of the variable capacitor and the identified particular parameter value, provide a likelihood indication that the tunable transmitter is positioned within a specified distance range of a body tissue interface.

13. The tunable transmitter of claim 12 , wherein the processing circuitry is further configured to:

when the likelihood indication indicates the tunable transmitter is within the specified distance range of the body tissue interface, communicate power and/or data with an implantable device using the excitation structure and the variable capacitor tuned to the particular parameter value.

14. The tunable transmitter of claim 11 , wherein the excitation structure is configured to energize a first one of the first and second conductive regions distributed about the first emitter; and

wherein the detecting the respective amounts of power reflected by the first emitter includes receiving a reflected signal using a second one of the first and second conductive regions.

15. The tunable transmitter of claim 10 , wherein the first drive signal includes a frequency between about 850 MHz and 950 MHz.

16. The tunable transmitter of claim 10 , wherein the first emitter is substantially symmetrical about an axis extending through the first and second conductive regions.

17. The tunable transmitter of claim 1 , wherein the excitation structure is a subwavelength conductive member.

18. A transmitter comprising:

an excitation structure configured to receive an excitation signal;

a signal generator coupled to the excitation structure;

a first substrate;

a first emitter comprising first and second conductive regions provided on a first surface of the first substrate and spaced apart from the excitation structure;

a variable capacitor coupling the first and second conductive regions of the first emitter, the variable capacitor configured to tune a resonant frequency of the transmitter; and

processing circuitry configured to:

cause the signal generator to energize the excitation structure with a first drive signal having a first frequency; and

sweep capacitance values of the variable capacitor to change a capacitive coupling between the first and second conductive regions of the first emitter to tune the first emitter to multiple different resonant frequencies at respective multiple instances;

wherein the processing circuitry is further configured to:

for each of the multiple different resonant frequencies, detect respective amounts of power reflected by the first emitter when the first emitter is energized by the first drive signal;

identify a particular capacitance value, of the swept capacitance values, corresponding to a detected minimum amount of power reflected by the first emitter; and

adjusting the variable capacitor to the particular capacitance value.

19. The transmitter of claim 18 , wherein the processing circuitry is further configured to:

based on both capacitance value states of the variable capacitor and the identified particular capacitance value, provide a likelihood indication that the transmitter is positioned within a specified distance range of a body tissue interface; and

communicate power and/or data with an implantable device using the excitation structure and the variable capacitor tuned to the particular capacitance value when the likelihood indication indicates the transmitter is within the specified distance range of the body tissue interface.

20. The transmitter of claim 18 , wherein the first conductive region of the first emitter comprises an inner disc region and the second conductive region of the first emitter comprises an outer annular region, and wherein the excitation structure extends at least partially over the inner disc region.

21. The transmitter of claim 18 , wherein the first drive signal has a frequency between 850 MHz and 950 MHz.

Assignments (2)
SECURITY INTEREST Recorded May 18, 2026
From: NEUSPERA MEDICAL INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY
Reel/Frame 075589/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2021
From: YEH, ALEXANDER; ZHANG, HUI; BURPEE ELLSWORTH, THOMAS, III; JUNCO, ELIA; SCHELLENBERG, STEPHEN JAMES; BOLING, CARL LANCE
To: NEUSPERA MEDICAL INC.
Reel/Frame 055573/0176 →
Continuity (6)
Continuation 16220815 · Dec 14, 2018
Provisional Application 62756648 · Nov 7, 2018
Provisional Application 62701062 · Jul 20, 2018
Provisional Application 62656637 · Apr 12, 2018
Provisional Application 62656675 · Apr 12, 2018
Related Publication 20210361940A1 · Nov 25, 2021
References Cited (115)
US 5086773A · Ware · 1992 [cited by applicant]
US 7191013B1 · Miranda et al. · 2007 [cited by applicant]
US 7202790B2 · Copeland et al. · 2007 [cited by applicant]
US 8634928B1 · O'Driscoll et al. · 2014 [cited by applicant]
US 9461648B1 · Lee et al. · 2016 [cited by applicant]
US 10485980B2 · Yeh et al. · 2019 [cited by applicant]
US 10561842B2 · Yeh et al. · 2020 [cited by applicant]
US 11596794B2 · Yeh et al. · 2023 [cited by applicant]
US 20040250820A1 · Forsell · 2004 [cited by applicant]
US 20050105917A1 · Narusawa et al. · 2005 [cited by applicant]
US 20060038597A1 · Becker et al. · 2006 [cited by applicant]
US 20060253107A1 · Hashimshony et al. · 2006 [cited by applicant]
US 20080269740A1 · Bonde et al. · 2008 [cited by applicant]
US 20090284220A1 · Toncich et al. · 2009 [cited by applicant]
US 20100109966A1 · Mateychuk · 2010 [cited by examiner]
US 20110148519A1 · Drogi et al. · 2011 [cited by applicant]
US 20110166629A1 · Dion et al. · 2011 [cited by applicant]
US 20120119698A1 · Karalis et al. · 2012 [cited by applicant]
US 20140031837A1 · Perryman et al. · 2014 [cited by applicant]
US 20140031903A1 · Mashiach · 2014 [cited by examiner]
US 20140036409A1 · Stevenson et al. · 2014 [cited by applicant]
US 20140203823A1 · Joshi · 2014 [cited by examiner]
US 20150066155A1 · Haque · 2015 [cited by examiner]
US 20160344238A1 · Yeh et al. · 2016 [cited by applicant]
US 20170001003A1 · Pivonka et al. · 2017 [cited by applicant]
US 20170095667A1 · Yakovlev et al. · 2017 [cited by applicant]
US 20170125897A1 · Rubin · 2017 [cited by examiner]
US 20170214127A1 · Newham et al. · 2017 [cited by applicant]
US 20170271919A1 · Von Novak, III et al. · 2017 [cited by applicant]
US 20180050208A1 · Shuros et al. · 2018 [cited by applicant]
US 20180071540A1 · Poon et al. · 2018 [cited by applicant]
US 20180085593A1 · Fayram et al. · 2018 [cited by applicant]
US 20180289971A1 · Yeh et al. · 2018 [cited by applicant]
US 20180294676A1 · Davlantes · 2018 [cited by applicant]
US 20190184159A1 · Yeh et al. · 2019 [cited by applicant]
US 20190290923A1 · Yeh et al. · 2019 [cited by applicant]
US 20200155843A1 · Yeh et al. · 2020 [cited by applicant]
AU 2019252904B2 · 2022 [cited by applicant]
AU 2022221472 · 2024 [cited by applicant]
CN 102769440A · 2012 [cited by applicant]
CN 110461218A · 2019 [cited by applicant]
CN 112673567 · 2024 [cited by applicant]
JP 2009518116 · 2009 [cited by applicant]
JP 2013521676A · 2013 [cited by applicant]
JP 2016518219 · 2016 [cited by applicant]
JP 2016149783A · 2016 [cited by applicant]
JP 2016538090A · 2016 [cited by applicant]
JP 2018514366A · 2018 [cited by applicant]
JP 2018532501A · 2018 [cited by applicant]
JP 7261814B2 · 2023 [cited by applicant]
WO WO2011024355A1 · 2011 [cited by applicant]
WO WO2011089676A1 · 2011 [cited by applicant]
WO WO2015039108A2 · 2015 [cited by applicant]
WO WO2015179225A1 · 2015 [cited by applicant]
WO 2017070372 · 2017 [cited by applicant]
WO WO2018140983A1 · 2018 [cited by applicant]
WO WO2019200285A1 · 2019 [cited by applicant]
“Chinese Application Serial No. 201980039503.0, Office Action malled Jan. 13, 2021”, with English translation, 2 pages. [cited by applicant]
“U.S. Appl. No. 16/722,593, Restriction Requirement mailed Apr. 9, 2021”, 8 pgs. [cited by applicant]
U.S. Appl. No. 16/220,815 U.S. Pat. No. 10,561,842, filed Dec. 14, 2018, Layered Midfield Transmitter With Dielectric Tuning. [cited by applicant]
U.S. Appl. No. 16/722,593, filed Dec. 20, 2019, Enhanced Wireless Comniunication and Power Transfer Between External and Implanted Devices. [cited by applicant]
“Canadian Application Serial No. 3,096,463, Office Action mailed Oct. 20, 2021”, 5 pages. [cited by applicant]
“Australian Application Serial No. 2019252904, First Examination Report mailed Nov. 5, 2021”, 5 pages. [cited by applicant]
“European Application Serial No. 19785104.1, Partial Supplementary European Search Report mailed Dec. 10, 2021”, 12 pages. [cited by applicant]
“U.S. Appl. No. 16/722,593, Non Final Office Action mailed May 12, 2022”, 5 pgs. [cited by applicant]
“Australian Application Serial No. 2019252904, Response Filed Apr. 6, 2022 to First Examination Report mailed Nov. 5, 2021”, 10 pgs. [cited by applicant]
“Canadian Application Serial No. 3,096,463, Response filed Feb. 17, 2022 to Office Action mailed Oct. 20, 2021”, 17 pgs. [cited by applicant]
“European Application Serial No. 19785104.1, Extended European Search Report mailed Apr. 5, 2022”, 13 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-554854, Response Filed Apr. 4, 2022 to Notification of Reasons for Refusal mailed Feb. 1, 2022”, W/ English Claims, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/004,894,312 Amendment filed Jul. 17, 2019”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/004,894, Notice of Allowance mailed Jun. 12, 2019”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/004,894, Response filed May 6, 2019 to Restriction Requirement mailed Apr. 3, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/004,894, Restriction Requirement mailed Apr. 3, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/220,815, Non Final Office Action mailed Sep. 10, 2019”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/220,815, Notice of Allowance mailed Dec. 11, 2019”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/220,815, Response filed Jun. 24, 2019 to Restriction Requirement—Prioritized Examination mailed May 21, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/220,815, Response filed Sep. 27, 2019 to Non-Final Office Action mailed Sep. 10, 2019”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/722,593, Preliminary Amendment filed Feb. 7, 2020”, 7 pgs. [cited by applicant]
“Australian Application Serial No. 2018213427, First Examination Report mailed Oct. 25, 2019”, 3 pgs. [cited by applicant]
“Australian Application Serial No. 2018213427, Response filed Dec. 18, 2019 to First Examination Report mailed Oct. 25, 2019”, 9 pgs. [cited by applicant]
“European Applicatioin Serial No. 18745034.1, Response filed Mar. 27, 2020 to Communication Pursuant to Rules 161(1) and 162 EPC mailed Oct. 11, 2019”, 31 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/016051, International Preliminary Report on Patentability mailed Aug. 8, 2019”, 9 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/016051, International Search Report mailed May 10, 2018”, 5 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/016051, Invitation to Pay Add'l Fees and Partial Search Rpt mailed Mar. 23, 2018”, 2 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/016051, Written Opinion mailed May 10, 2018”, 7 pgs. [cited by applicant]
“International Application Serial No. PCT/US2019/027270, International Preliminary Report on Patentability mailed Jul. 27, 2020”, 10 pgs. [cited by applicant]
“International Application Serial No. PCT/US2019/027270, International Search Report mailed Aug. 19, 2019”, 5 pgs. [cited by applicant]
“International Application Serial No. PCT/US2019/027270, Invitation to Pay Additional Fees mailed Jun. 19, 2019”, 3 pgs. [cited by applicant]
“International Application Serial No. PCT/US2019/027270, Response to Written Opinion filed Feb. 12, 2020 to Written Opinion mailed Aug. 19, 2019”, 41 pgs. [cited by applicant]
“International Application Serial No. PCT/US2019/027270, Written Opinion mailed Aug. 19, 2019”, 9 pgs. [cited by applicant]
“Near and far field”, Wikipedia contributors, The Free Encyclopedia, Retrieved from the Internet: <URL: https://en.wikipedia.org/wiki/Near_and_far_field>, (Accessed Sep. 4, 2019), 11 pages. [cited by applicant]
“Stripline”, Wikipedia contributors, Wikipedia, The Free Encyclopedia, [Online]. Retrieved from the Internet: <URL: https://en.wikipedia.org/wiki/Stripline>, (Accessed Sep. 4, 2019), 3 pages. [cited by applicant]
“Japanese Application Serial No. 2020-554854, Notification of Reasons for Refusal mailed Feb. 1, 2022”, with English translation, 13 pages. [cited by applicant]
“European Application Serial No. 19785104.1, Response to Communication pursuant to Rules 161(2) and 162 EPC filed May 26, 2021”, 38 pages. [cited by applicant]
“U.S. Appl. No. 16 722,593, Response filed Jun. 9, 2021 to Restriction Requirement mailed Apr. 9, 2021”, 9 pages. [cited by applicant]
“U.S. Appl. No. 16/722,593, Corrected Notice of Allowability mailed Feb. 1, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/722,593, Notice of Allowability mailed Nov. 10, 2022”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/722,593, Notice of Allowance mailed Nov. 1, 2022”, 5 pgs. [cited by applicant]
“Canadian Application Serial No. 3096483, Examiner's Rule 86 2 Requisition mailed Nov. 4, 2022”, 4 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-554854, Examiners Decision of Final Refusal mailed Sep. 27, 2022”, w/ English Translation, 15 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-554854, Response Filed Jan. 20, 2023 to Examiners Decision of Final Refusal mailed Sep. 27, 2022”, W/ English Claims, 17 pgs. [cited by applicant]
“Australian Application Serial No. 2022221472, First Examination Report mailed Jun. 30, 2023”, 4 pgs. [cited by applicant]
“Canadian Application Serial No. 3096483, Response Filed Feb. 15, 2023 to Examiner's Rule 86 2 Requisition mailed Nov. 4, 2022”, 5 pgs. [cited by applicant]
“European Application Serial No. 19785104.1, Response Filed Nov. 7, 2022 Extended European Search Report mailed Apr. 5, 2022”, 9 pgs. [cited by applicant]
“Canadian Application Serial No. 3,096,463, Examiners Rule 86(2) Requisition mailed Oct. 5, 2023”, 3 pgs. [cited by applicant]
“Australian Application Serial No. 2022221472, Response Filed Nov. 16, 2023 First Examination Report mailed Jun. 30, 2023”, 14 pgs. [cited by applicant]
“Canadian Application Serial No. 3,096,463, Response filed Jan. 30, 2024 to Examiners Rule 86(2) Requisition mailed Oct. 5, 2023”, 6 pgs. [cited by applicant]
“Japanese Application Serial No. 2023-007138, Notification of Reasons for Refusal mailed Feb. 27, 2024”, w English translation, 9 pgs. [cited by applicant]
“Chinese Application Serial No. 201980039503.0, Office Action mailed Apr. 8, 2024”, w English translation, 21 pgs. [cited by applicant]
“Chinese Application Serial No. 201980039503.0, Response filed Jun. 26, 2024 to Office Action mailed Apr. 8, 2024”, w current English claims, 126 pgs. [cited by applicant]
“Japanese Application Serial No. 2023-007138, Response filed Jul. 16, 2024 to Notification of Reasons for Refusal mailed Feb. 27, 2024”, w current English claims, 12 pgs. [cited by applicant]
“Chinese Application Serial No. 201980039503.0 , Response to Examiner Telephone Interview Filed Aug. 2, 2024”, w English Claims, 10 pgs. [cited by applicant]
“Japanese Application Serial No. 2023-007138, Final Notification of Reasons for Refusal mailed Oct. 8, 2024”, w English Translation, 10 pgs. [cited by applicant]
“Japanese Application Serial No. 2023-007138, Response filed Nov. 26, 2024 to Final Notification of Reasons for Refusal mailed Oct. 8, 2024”, w current English claims, 12 pgs. [cited by applicant]
“European Application Serial No. 19785104.1, Communication Pursuant to Article 94(3) EPC mailed Mar. 6, 2025”, 5 pgs. [cited by applicant]